

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

|                       |  |
|-----------------------|--|
| <b>Name of entity</b> | <b>Botanix Pharmaceuticals Limited</b> |
| <b>ACN</b>            | <b>009 109 755</b>                     |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |                 |
|----------------------------|-----------------|
| <b>Name of Director</b>    | Daniel Sharp    |
| <b>Date of last notice</b> | 3 December 2024 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |   |
|---|---|
| <b>Direct or indirect interest</b>  | Indirect  |
| <b>Nature of indirect interest (including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | DJMB Corporate Pty Ltd -<br>Mr Sharp is a director of DJMB Corporate Pty Ltd  |
| <b>Date of change</b>   | 20 March 2025   |
| <b>No. of securities held prior to change</b>   | <b>DJMB Corporate Pty Ltd</b> - Mr Sharp is a director of DJMB Corporate Pty Ltd <ul style="list-style-type: none"><li>• 2,131,313 Fully Paid Ordinary Shares</li><li>• 4,000,000 Unlisted Options exercisable at \$0.094 each, expiring 22 March 2025</li><li>• 333,333 Performance Rights (expiring 30 November 2026)</li><li>• 3,000,000 Performance Rights (expiring 2 December 2029)</li></ul> |
| <b>Class</b>  | Fully paid ordinary shares / Unlisted Options exercisable at \$0.094 each, expiring 22 March 2025   |
| <b>Number acquired</b>  | 3,111,145 fully paid ordinary shares  |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

|  |  |
|--|--|
| <b>Number disposed</b>   | 4,000,000 Unlisted Options exercisable at \$0.094 each, expiring 22 March 2025   |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>   | Nil – issued in accordance with the cashless exercise facility under the terms and conditions of the Company's Employee Awards Plan.   |
| <b>No. of securities held after change</b>   | <b>DJMB Corporate Pty Ltd</b> - Mr Sharp is a director of DJMB Corporate Pty Ltd <ul style="list-style-type: none"> <li>• 5,242,458 Fully Paid Ordinary Shares</li> <li>• 333,333 Performance Rights (expiring 30 November 2026)</li> <li>• 3,000,000 Performance Rights (expiring 2 December 2029)</li> </ul> |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | Issue of fully paid ordinary shares on exercise of options in accordance with the terms of the Company's Employee Awards Plan.   |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |     |
|---|-----|
| <b>Detail of contract</b>   | N/A |
| <b>Nature of interest</b>   | N/A |
| <b>Name of registered holder (if issued securities)</b>   | N/A |
| <b>Date of change</b>   | N/A |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A |
| <b>Interest acquired</b>  | N/A |
| <b>Interest disposed</b>  | N/A |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small>   | N/A |
| <b>Interest after change</b>  | N/A |

+ See chapter 19 for defined terms.

**Part 3 Closed Period**

|   |     |
|---|-----|
| Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? | No  |
| If so, was prior written clearance provided to allow the trade to proceed during this period?   | N/A |
| If prior written clearance was provided, on what date was this provided?  | N/A |

---

+ See chapter 19 for defined terms.